Uncategorized

Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked

In the high-stakes world of pharmaceuticals, the battle over patent rights isn’t just about innovation—it’s about who profits, who gets blocked, and ultimately, who has access to life-saving medicines. As the industry faces mounting pressure to balance…

Win the Patent War Before the Drug Goes Generic: How Paragraph IV Challenges and Pay-for-Delay Settlements Decide Who Gets Paid — and Who Gets Blocked Read Post »

General Biotechnology

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War

In the high-stakes world of biopharmaceutical innovation, the battle lines are being redrawn—not just by groundbreaking therapies, but by the complex legal and regulatory frameworks that govern them. As the biopharma industry approaches a $400 billion …

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Shape the $400 Billion Biologics War Read Post »

Uncategorized

Find the Money Before the Patent Dies: How to Identify Out-Licensing Targets Near Drug Patent Expiry — and Capture Value That Most Companies Leave on the Table

In the high-stakes world of pharmaceutical innovation, timing is everything. Yet, many companies overlook a critical window—one where the true value of a drug is still within reach, but slipping away fast. The question is: Are you positioning your orga…

Find the Money Before the Patent Dies: How to Identify Out-Licensing Targets Near Drug Patent Expiry — and Capture Value That Most Companies Leave on the Table Read Post »

Biotechblog
Scroll to Top